Spetty, excellent, factual and blunt post that, to me is balanced and honestly presents many facts.
The otcbb landscape is littered with many, many promising start up biotechs that never made through their r and d because of toxic financing, etc., that eventually killed them
Sad, really, when you think of all the products that could be helping humanity today, that got killed because of alleged big pharma roadblocks, toxic financing and stock price manipulation legally and illegally.
There are still so many developments to unfold How they do and how they are perceived by the general retail public will determine where we go price-wise. I'ts time for the Board, Langer and Rabin to creatvely come up with solutions over what may be this last big hurdle, if clinicals continue going positively and december/january brings blockbuster news.
As suggested, all this concern, negativity and possible short term weakness could end up being nothing in the larger scheme of things if ACTC survives and turns out to be the blockbuster many of us have hoped for and feel is still very possible.